Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 943-947

  Dunsford, M L ^a,b   Mead, G M ^a   Bateman, A C ^a   Cook, T ^a   Tung, K ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

Gemcitabine docetaxel; Pulmonary toxicity

Indexed keywords

DEOXYCYTIDINE; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; PREDNISOLONE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DOSE CALCULATION; DYSPNEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0032830832     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008377819875     Document Type: Article

References (34)

1. Sternberg CN. The treatment of advanced bladder cancer. Ann Oncol 1995; 6: 113-26.
2. Scott B, Saxman KJ, Probert LH. Longterm follow up of a phase III intergroup study of cisplatin alone or in combinaton with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A Co-Operative Group Study. J Clin Oncol 1997; 15: 2564-9.
3. Stadler WM, Kuzel T, Roth B et al. Phase II study of single-agent gemcitabine in previous untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-8.
4. Yokoyama A, Nakai Y, Yoneda S et al. Activity of gemcitabine in the treatment of patients with non-small-cell lung cancer: A multicentre phase Il study. Anti Cancer Drugs 1997; 8: 574-81.
5. Shepherd F A, Cormier Y, Burkes R et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer. Semin Oncol 1997; 24: 27-30.
6. Santoro A, Devizzi L, Bonfante V et al. Phase II study with gemcitabine in pre-treated patients with Hodgkins (HD) and non-Hodgkins lymphoma (NHL): Results of a multicentre study. PROC ASCO 16; 1997.
7. Fukuoka M, Takada M, Yokoyama A et al. Phase II studies of gemcitabine for non-small-cell lung cancer in Japan. Semin Oncol 1997; 24: S7-46.
8. Carmichael J, Fink U, Russell RCG et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-5.
9. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
10. Rothenberg ML, Eckardt, JR, Stephens W et al. A phase II trial of gemcitabine and paclitaxel administered on an every other week schedule. Ann Oncol 1996; 7 (Abstr 3191).
11. Sanchez-Rovira P, Mohedano N, Moreno MA et al. Preliminary results from an early phase II combination of gemcitabine and Taxol in metastatic breast cancer. Eur J Cancer 1997; 33 (Abstr 685).
12. Georgoulias V, Kouroussis N, Androulakis N et al. Front-line treatment of advanced non-small-cell lung cancer (NSCLC) with docetaxel (D) and gemcitabine (G): A multicentre phase II trial. Proc ASCO 1988; 17: 1819.
13. Paviakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-91.
14. Merad M, Le Cesne A, Baldeyrou P et al. Docetaxel and interstitial pulmonary injury. Ann Oncol 1997; 8: 191-4.
15. Ramanathan RK, Belani CP. Transient pulmonary infiltrates: A hypersensitivity reaction to paclitaxel. Ann Intern Med 1996: 124: 278.
16. Ramesh K, Ramanathan RK, Holvert MJ, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996; 110: 289-91.
17. Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997; 31: 1471-4.
18. Schweitzer VG, Juillard GJF, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76: 1069-72.
19. Reckzeh B, Merte H, Pfluger KH et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996; 14: 1071-6.
20. Ayoub J-P, North L, Greer J et al. Pulmonary changes in patients with lymphoma who receive paclitaxel. J Clin Oncol 1997; 15: 2476-7.
21. Bonomi P, Faber P L, Warren W et al. Postoperative broncho-pulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol 1997; 24 (Suppl 12): 123-9.
22. Richenel TO, Tham T, Peters WG et al. Pulmonary complications of cytosine-arabinoside therapy: Radiographic findings. AJR 1987; 149: 23-7.
23. Plunkett W, Huang P, Xu Y et al. Gemcitabine: Metabolism, mechanisms of action and self-potentiation. Semin Oncol 1995; 22: 3-10.
24. Tonato M, Mosconi AM, Martin C. Safety profile of gemcitabine. Anti-Cancer Drugs 1995; 6: 27-32.
25. Jehn U, Goldel N, Rienmuller R, Wilmanns W. Non-cardiogenic pulmonary complicating intermediate and high-dose ARA C treatment for relapsed acute leukaemia. Med Oncol Tumour Pharmacother 1988; 5: 41-7.
26. Shearer P, Katz J, Bozeman P et al. Pulmonary insufficiency complicating therapy with high-dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukaemia. Cancer 1994; 74: 1953-8.
27. Haupt HM, Hutchins GM, Moore GW. Ara-C lung: Non-cardiogenic pulmonary oedema complicating cytosine arabinoside therapy of leukaemia. Am J Med 1981; 70: 256-61.
28. Anderson BS, Cogan BM, Keating MJ et al. Subacute pulmonary failure complicating therapy with high-dose ara-C in acute leukaemia. Cancer 1985; 56: 2181-4.
29. Nelson R, Tarasoff P. Dyspnoea with gemcitabine is commonly seen, often diseaese related, transient and rarely severe. Eur J Cancer 1995; 31A (Suppl 5): 5197-8.
30. Gatzemeier U, Manegold C, Eberhard W et al. A phase II trial of gemcitabine and ifosfamide in non-small-cell lung cancer. Semin Oncol 1997; 24 (Suppl 8): 36-8.
31. Schewach DS, Lawrence TS. Radiosensitization of human tumour cells by gemcitabine in vitro. Semin Oncol 1995; 22 (Suppl 11): 68-71.
32. Scalliet P, Goor C, Galdermans D et al. Gemzar (gemcitabine) with thoracic radiotherapy - a phase II pilot study in cheonaive patients with advanced non-small-cell lung cancer (NSCLC). Proc ASCO 1998; 17: 1923: 499a.
33. Georgoulia V, Kourousis C, Andoulakis N et al. Docetaxel (Taxotere) and gemcitabine in the treatment on non-small-cell lung cancer. Preliminary results. Semin Oncol 1997; 4 (Suppl 14): 22-25.
34. Mauer AM, Masters GA, Haraf DJ et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998; 16: 159-64.